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Disseminated intravascular coagulation (DIC) in sepsis causes microthrombus formation and disturbs the organ perfusion that promotes organ failure. As a result, the mortality rate increases to nearly double when the patients complicate DIC. Although anticoagulant therapies for severe sepsis and septic shock have been challenged since the early 2000s, the therapeutic benefit could not been proven in any of the drugs. Subanalyses of large‐scale randomized controlled trials examining the effect of antithrombin and activated protein C have shown a trend toward a favorable effect in the patients with sepsis‐induced DIC.[1](#ams2372-bib-0001){ref-type="ref"} Also, recent large‐scale *post hoc* analyses consistently reported the survival benefit in patients with sepsis‐induced DIC.[2](#ams2372-bib-0002){ref-type="ref"} Thus, we expected that "tailored medicine (anticoagulant therapy for the patients with severe coagulation disorder)" could be the first shot to open the tight gate of sepsis trials.

Based on the aforementioned backgrounds, the effects of recombinant human thrombomodulin (ART‐123, Recomodulin; Asahi Kasei Pharma, Tokyo, Japan) for the patients with sepsis and coagulation disorder have been examined in a multinational, randomized, placebo‐controlled, double‐blinded phase III trial (SCARLET). According to the press release \[<http://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html>\], 28‐day mortality was improved 2.6% (ART‐123 group, 26.8% versus placebo group, 29.4%) in a total of 800 sepsis patients (ART‐123 group, *n* = 395; placebo group, *n* = 405) with organ dysfunction and coagulopathy (platelet count \<150 × 10^9^/L and prothrombin time--international normalized ratio \> 1.4), but the difference did not reach statistical significance. The article also reported that patients who met the entry criteria at baseline and received the treatment for more than 4 days showed a mortality difference of approximately 7%.

Why did this trial fail again? The selection of the patients could be a reason. However, we think the end‐point could be another reason. Although the 28‐day mortality rate has been the gold standard for sepsis studies, settings of alternative methods to measure benefit should be considered for the development of new therapeutic methods.[3](#ams2372-bib-0003){ref-type="ref"} In a previous randomized controlled trial undertaken by the Japanese Association for Acute Medicine,[4](#ams2372-bib-0004){ref-type="ref"} antithrombin supplementation succeeded in showing a significant improvement in DIC resolution in patients with sepsis‐associated DIC without improving 28‐day mortality, likely due to the small number of subjects. To succeed in the conventional sepsis trial, more than 1,000 cases should be accumulated, and we are afraid that very few trials will be attempted after the failure of SCARLET. Vincent *et al*.[5](#ams2372-bib-0005){ref-type="ref"} suggested the need to include morbidity in addition to mortality as so many factors, such as age, comorbidities, and other factors, influence the overall mortality. To assess the treatment effect punctually, we think that change in other factors, such as improvement in organ failure scores, should be examined. Similarly, the resolution of DIC could be an alternative indicator of anticoagulant therapies. In conclusion, we think we should not discard recombinant thrombomodulin as a potential therapy and examine the detail of SCARLET carefully. In addition, we should continue the search for the practical end‐points to judge the effectiveness of therapeutic drugs properly. A new era never arrives without effort.
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